Cargando…

Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases

Brain metastases (BM) cause morbidity and mortality in patients with non-small cell lung cancer (NSCLC). The use of upfront epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and withholding of whole-brain radiation therapy (WBRT) is controversial. We aim to investigate the im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chien-Hung, Lee, Hsin-Hua, Chuang, Hung-Yi, Hung, Jen-Yu, Huang, Ming-Yii, Chong, Inn-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721307/ https://www.ncbi.nlm.nih.gov/pubmed/31370314 http://dx.doi.org/10.3390/cancers11081092

Ejemplares similares

Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases
por: Lee, Hsin-Hua, et al.
Publicado: (2019)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
por: Kuo, Chia-Yu, et al.
Publicado: (2022)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

Whole brain radiotherapy with radiosensitizer for brain metastases
por: Viani, Gustavo Arruda, et al.
Publicado: (2009)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
por: Lu, Yunyun, et al.
Publicado: (2016)

The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations
por: Kuo, Chia-Yu, et al.
Publicado: (2019)

Whole-Brain Radiotherapy Can Improve the Survival of Patients with Multiple Brain Metastases from Non-Small Cell Lung Cancer Treated by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Chen, Cheng, et al.
Publicado: (2020)

Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)
por: Zhu, Qianqian, et al.
Publicado: (2017)

Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
por: Yun, Po-Jen, et al.
Publicado: (2019)

Retrospective study of hypofractionated stereotactic radiotherapy combined with whole brain radiotherapy for patients with brain metastases
por: Xie, Xue-Yi, et al.
Publicado: (2022)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases
por: Jiang, Cecilia, et al.
Publicado: (2021)

Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study
por: Jiang, Ai-Ying, et al.
Publicado: (2018)

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases
por: Luo, Shuimei, et al.
Publicado: (2015)

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment
por: Tallet, Agnes V, et al.
Publicado: (2012)

Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors
por: Ni, Zexu, et al.
Publicado: (2019)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

Meta‐analysis of whole‐brain radiotherapy plus temozolomide compared with whole‐brain radiotherapy for the treatment of brain metastases from non‐small‐cell lung cancer
por: Xin, Yong, et al.
Publicado: (2018)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
por: Tsai, Ming-Ju, et al.
Publicado: (2018)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
por: Lee, Tai-Huang, et al.
Publicado: (2022)

Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
por: Bhandari, Shruti, et al.
Publicado: (2021)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
por: Wang, Yu, et al.
Publicado: (2023)

Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer
por: Lee, Hsin-Hua, et al.
Publicado: (2020)

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014)

Re-Whole Brain Radiotherapy May Be One of the Treatment Choices for Symptomatic Brain Metastases Patients
por: Ono, Takashi, et al.
Publicado: (2022)

Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?
por: Nieder, Carsten, et al.
Publicado: (2013)

Advances in radiotherapy for brain metastases
por: Gondi, Vinai, et al.
Publicado: (2021)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

Whole-Brain Radiotherapy vs. Localized Radiotherapy after Resection of Brain Metastases in the Era of Targeted Therapy: A Retrospective Study
por: Koo, Jaho, et al.
Publicado: (2021)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible
por: Fogarty, Gerald B, et al.
Publicado: (2014)

Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy
por: Frisk, Gabriella, et al.
Publicado: (2017)

Effectiveness of temozolomide combined with whole brain radiotherapy for non‐small cell lung cancer brain metastases
por: Zhu, Ying, et al.
Publicado: (2018)

From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC
por: Protopapa, Maria, et al.
Publicado: (2019)

Survival time and prognostic factors after whole-brain radiotherapy of brain metastases from of breast cancer
por: Okada, Yukinori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bhfs112t5oddkqr79afsgls78h